| Diabetes Mellitus, Non-Insulin-Dependent
Lyumjev vs Steglujan
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Lyumjev vs Steglujan with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSteglujan has a higher rate of injection site reactions vs Lyumjev based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Steglujan but not Lyumjev, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Lyumjev
Steglujan
At A Glance
SC injection
With each meal
Rapid-acting insulin analog
Oral
Once daily
SGLT2 inhibitor + DPP-4 inhibitor
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Diabetes Mellitus, Non-Insulin-Dependent Administer U-100 or U-200 SC at meal start or within 20 minutes after starting a meal into abdomen, upper arm, thigh, or buttocks; U-100 also available via CSII insulin pump or IV infusion (under medical supervision, diluted to 1 unit/mL); individualize dose based on metabolic needs and glucose monitoring.
Diabetes Mellitus, Non-Insulin-Dependent Starting dose 5 mg ertugliflozin/100 mg sitagliptin orally once daily in the morning, with or without food; may increase to 15 mg/100 mg once daily for additional glycemic control; not recommended if eGFR less than 45 mL/min/1.73 m2; withhold at least 4 days before surgery or procedures associated with prolonged fasting.
Contraindications
- Episodes of hypoglycemia
- Hypersensitivity to insulin lispro-aabc or any excipient in LYUMJEV
- Severe renal impairment (eGFR less than 30 mL/min/1.73 m2), end-stage renal disease (ESRD), or on dialysis
- Hypersensitivity to sitagliptin, ertugliflozin, or any excipient in STEGLUJAN
Adverse Reactions
Most common (>=5%) Nasopharyngitis, upper respiratory tract infection, infusion site reaction, infusion site pain
Serious Hypoglycemia (including severe), severe hypersensitivity reactions (anaphylaxis, angioedema, bronchospasm, hypotension, shock)
Postmarketing Localized cutaneous amyloidosis at injection site, hyperglycemia or hypoglycemia associated with injection into areas of localized cutaneous amyloidosis
Most common (>=2%) Female genital mycotic infections, male genital mycotic infections, urinary tract infections, headache, vaginal pruritus, increased urination, nasopharyngitis, back pain, weight decreased, thirst
Serious Diabetic ketoacidosis, pancreatitis, lower limb amputation, acute renal failure, volume depletion, urosepsis and pyelonephritis, heart failure, hypoglycemia (with insulin or insulin secretagogues), necrotizing fasciitis of the perineum (Fournier's Gangrene), hypersensitivity reactions, severe and disabling arthralgia, bullous pemphigoid
Postmarketing Necrotizing fasciitis of the perineum, angioedema, rash, anaphylaxis, urticaria, cutaneous vasculitis, Stevens-Johnson syndrome, pruritus, hepatic enzyme elevations, acute pancreatitis, worsening renal function, severe and disabling arthralgia, myalgia, rhabdomyolysis
Pharmacology
Rapid-acting human insulin analog that binds insulin receptors to stimulate peripheral glucose uptake in skeletal muscle and fat and inhibit hepatic glucose production, while also inhibiting lipolysis and proteolysis and enhancing protein synthesis.
STEGLUJAN combines ertugliflozin, an SGLT2 inhibitor that reduces renal reabsorption of filtered glucose and increases urinary glucose excretion, and sitagliptin, a DPP-4 inhibitor that slows inactivation of incretin hormones (GLP-1 and GIP), thereby increasing insulin release and decreasing glucagon secretion in a glucose-dependent manner.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Lyumjev
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (6/12) · Qty limit (8/12)
Steglujan
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (7/12) · Qty limit (9/12)
UnitedHealthcare
Lyumjev
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Steglujan
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Lyumjev
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (3/3) · Qty limit (0/3)
Steglujan
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Lyumjev.
No savings programs available for Steglujan.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
LyumjevView full Lyumjev profile
SteglujanView full Steglujan profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.